Public Company

Clene Nanomedicine, Inc.


Our team of visionary innovators and pharmaceutical executives have proven track-records of excellence, expertise, and willingness to push therapeutic development beyond its traditional bounds. Our approach implements elemental solutions to therapeutic challenges results in new opportunities and insights into the world’s most challenging diseases. Our singular vision is to transform the treatment of neurodegenerative diseases that steal away peoples’ lives, allowing people to thrive.


Founded 2013
Type Public
Location Salt Lake City, Utah, USA


CLNN $1.16 -5.31% $(0.07)

Latest News

Clene Appoints Neurology Expert to Executive Team Mar 16, 2023 GlobeNewswire Inc. SALT LAKE CITY, March 16, 2023 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine,...
Is Clene (CLNN) Stock Outpacing Its Medical Peers This Year? Mar 16, 2023 Zacks Investment Research Here is how Clene Inc. (CLNN) and The Cooper Companies (COO) have performed compared to their sector so far this year.
Clene Inc. (CLNN) Reports Q4 Loss, Tops Revenue Estimates Mar 13, 2023 Zacks Investment Research Clene Inc. (CLNN) delivered earnings and revenue surprises of -6.67% and 73.33%, respectively, for the quarter ended December 2022. Do the numbers hold clues to...
Clene Reports Full Year 2022 Financial Results and Recent Operating Highlights Mar 13, 2023 GlobeNewswire Inc. SALT LAKE CITY, March 13, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine...
The Latest Analyst Ratings for Clene Mar 10, 2023 Benzinga Within the last quarter, Clene (NASDAQ:CLNN) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 7 0 0 0...